ÌÇÐÄvlog

This Viewpoint argues that conventional definitions of medication reconciliation overlook the need to identify the correct list of medicines for patients, and discusses the challenges involved in defining who should be involved in defining and maintaining that list.

This Viewpoint uses the example of the US FDA’s 2017 approval of desmopressin for treatment of nocturia to discuss the risks of approving a drug for symptoms rather than disease and the ways that the drug approval process is influenced by manufacturers and by overreliance on statistical vs clinical significance.

This Viewpoint describes measures needed for an effective NIH policy in which a single IRB would work with multiple local IRBs to ensure protection of participants in multisite trials.

This Viewpoint defines mindsets—frames of mind that orient beliefs or expectations—discusses how they can influence patients’ perceptions about treatment and self-efficacy, and proposes ways physicians might shape patients’ mindsets during clinical encounters to enhance treatment effectiveness.